Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer DiseaseEdmond Teng, Carlo de Lena, Mira Blendstrup et al.|JAMA Neurology|2022Cited by 188
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecília Monteiro, William Alvin McElveen, Balázs István Tóth et al.|Neurology|2023Cited by 104